Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.

You may also be interested in...



LABA Label Changes Could Reinvigorate Single-Ingredient Products

FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs

FDA Scales Back LABA Safety Relabeling To Address Physician Worries

FDA has modified the safety relabeling it is rolling out for long-acting beta agonists to reflect physician concerns that an abrupt discontinuation of the products could be harmful to patients

LABA Label Changes Could Reinvigorate Single-Ingredient Products

FDA's new labeling and use guidelines for long-acting beta agonists may present some sales challenges, but also may create a new market for older drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS070335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel